InsiderClue
← All stocks

Inhibrx Biosciences, Inc.

INBX Net buying
CIK 0002007919 #2266 in the set updated 17 Sep 2026
Bought (1 mo)
$3.50M
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$279.01K
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$279.01K
5 of 5 sales
Net
+$3.22M
+$3.22M against sales at will

By person

6 insiders · 13 transactions
143×

Mark P. Lappe holds 143 times base salary in stock. $99.84M of shares against $695.25K in salary for 2025.

Salary from the company's own proxy. The shares are what Mark P. Lappe last reported holding, valued at $105.05, the price Common Stock was last bought or sold at on the open market here, on 15 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Lappe Mark
Chief Executive Officer
$2.65M (6)
—
+$2.65M
950,413
6.46%
$99.84M
+2.7%
Kayyem Jon Faiz
Director
$567.58K (1)
—
+$567.58K
1,483,406
10.08%
$155.83M
−2.0%
FORSYTH DOUGLAS
Director
$286.62K (1)
—
+$286.62K
227,064
1.54%
$23.85M
+1.1%
MANHARD KIMBERLY
Director
—
$279.01K (5)
−$279.01K
7,500
0.0510%
$787.88K
−25.0%
VIKING GLOBAL INVESTORS LP entity
10% owner
—
—
—
102,864
0.6989%
$10.81M
−77.3%
Vuori Kristiina MD
Director
—
—
—
20,443
0.1389%
$2.15M
+48.4%

Individual transactions

8
Insider
Date
Role
Action
Shares
Price
Amount
Lappe Mark
8 Sep 2026
Chief Executive Officer
Buy indirect
9,681
$112.28
$1.09M
Lappe Mark
8 Sep 2026
Chief Executive Officer
Buy indirect
1,219
$111.88
$136.38K
Lappe Mark
8 Sep 2026
Chief Executive Officer
Buy indirect
500
$108.24
$54.12K
Lappe Mark
8 Sep 2026
Chief Executive Officer
Buy indirect
1,100
$107.12
$117.84K
Lappe Mark
8 Sep 2026
Chief Executive Officer
Buy indirect
6,605
$100.64
$664.72K
Lappe Mark
8 Sep 2026
Chief Executive Officer
Buy indirect
5,895
$99.29
$585.34K
FORSYTH DOUGLAS
8 Sep 2026
Director
Buy indirect
2,500
$114.65
$286.62K
Kayyem Jon Faiz
8 Sep 2026
Director
Buy indirect
5,000
$113.52
$567.58K
Show all 13 transactions →

What was left out

Form 4 filings counted 5
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 5
Transactions with no price 0
Shares from compensation/vesting 0
History held since 30 May 2024